Market Place
Sourcing Support
Orbus Announces First Patient Enrolled in Ph 1 Study in Diagnosed Glioblastoma
06 Sep 2023 //
GLOBENEWSWIRE
Orbus Enters Agreement to Treatment of Rare Pediatric Syndrome with Eflornithine
10 Jan 2023 //
GLOBENEWSWIRE
Orbus’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment
19 Jan 2022 //
GLOBENEWSWIRE
Orbus Therapeutics Granted European Patent for Method of Use for Eflornithine
28 Sep 2021 //
GLOBENEWSWIRE
Orbus Therapeutics Announces Positive Outcome of Pre-Planned Futility Analysis
02 Mar 2021 //
GLOBENEWSWIRE
Orbus Therapeutics Receives U.S. Patent for Eflornithine Formulations
23 Dec 2020 //
GLOBENEWSWIRE
Orbus Therapeutics Receives U.S. Patent for Eflornithine Formulations
23 Dec 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.